Danielle Duffy
Overview
Explore the profile of Danielle Duffy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
682
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gibson C, Chi G, Duffy D, Bahit M, White H, Korjian S, et al.
J Am Coll Cardiol
. 2024 Sep;
84(22):2185-2192.
PMID: 39230545
Background: Following an acute myocardial infarction (AMI), patients remain at risk for subsequent cardiovascular (CV) events. In the AEGIS-II trial, CSL112, a human apolipoprotein A-I derived from plasma that enhances...
2.
Gibson C, Duffy D, Bahit M, Chi G, White H, Korjian S, et al.
Eur Heart J
. 2024 Sep;
45(47):5023-5038.
PMID: 39221651
Background And Aims: In the AEGIS-II trial (NCT03473223), CSL112, a human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity, did not significantly reduce the risk of the primary...
3.
Kingwell B, Duffy D, Clementi R, Velkoska E, Feaster J, Gibson C
J Am Heart Assoc
. 2024 May;
13(9):e033541.
PMID: 38700008
No abstract available.
4.
Povsic T, Korjian S, Bahit M, Chi G, Duffy D, Alexander J, et al.
J Am Coll Cardiol
. 2024 Apr;
83(22):2163-2174.
PMID: 38588930
Background: The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction...
5.
Gibson C, Duffy D, Korjian S, Bahit M, Chi G, Alexander J, et al.
N Engl J Med
. 2024 Apr;
390(17):1560-1571.
PMID: 38587254
Background: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has...
6.
Didichenko S, Velkoska E, Navdaev A, Greene B, Lorkowski S, Duffy D, et al.
Arterioscler Thromb Vasc Biol
. 2023 Mar;
43(6):855-869.
PMID: 36994730
Background: To characterize the effects of CSL112 (human APOA1 [apolipoprotein A1]) on the APOA1 exchange rate (AER) and the relationships with specific HDL (high-density lipoprotein) subpopulations when administered in the...
7.
Korjian S, Kazmi S, Chi G, Kalayci A, Lee J, Talib U, et al.
Eur Heart J Cardiovasc Pharmacother
. 2023 Feb;
9(4):387-398.
PMID: 36787889
Despite current standard of care treatment, the period shortly after acute myocardial infarction (AMI) is associated with high residual cardiovascular (CV) risk, with high rates of recurrent AMI and CV...
8.
Gibson C, Kazmi S, Korjian S, Chi G, Phillips A, Memar Montazerin S, et al.
J Cardiovasc Pharmacol Ther
. 2022 Oct;
27:10742484221121507.
PMID: 36282079
Introduction: Cholesterol efflux capacity (CEC) is impaired following acute myocardial infarction (AMI). CSL112 is an intravenous preparation of human plasma-derived apoA-I formulated with phosphatidylcholine (PC). CSL112 is intended to improve...
9.
Zheng B, Goto S, Clementi R, Feaster J, Duffy D, Dalitz P, et al.
Clin Transl Sci
. 2022 Aug;
15(10):2331-2341.
PMID: 35933730
CSL112 (apolipoprotein A-I [apoA-I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC). This...
10.
Kalayci A, Gibson C, Ridker P, Wright S, Kingwell B, Korjian S, et al.
Curr Atheroscler Rep
. 2022 May;
24(7):585-597.
PMID: 35524914
Purpose Of Review: The elevated adverse cardiovascular event rate among patients with low high-density lipoprotein cholesterol (HDL-C) formed the basis for the hypothesis that elevating HDL-C would reduce those events....